Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibroblast growth factor receptor 4 (FGFR4) is a receptor tyrosine kinase that belongs to the FGFR family. It plays a crucial role in cell proliferation, differentiation, migration, and metabolism. FGFR4 is activated by fibroblast growth factors (FGFs), leading to downstream signaling through MAPK/ERK and PI3K/AKT pathways. It is implicated in various cancers, including breast, ovarian, prostate, gastric, and pancreatic cancers, making it a therapeutic target. A common polymorphism, Gly388Arg, is associated with worse prognosis in several cancer types. Selective FGFR4 inhibitors are under development as cancer therapeutics.
Small molecule inhibitors selectively targeting the FGFR4 kinase domain, blocking its autophosphorylation and downstream signaling.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibroblast Growth Factor Receptor 4 (FGFR4).